Berlex to sell prefilled Magnevist syringes
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999.
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999. Prefilled syringes will come in 10-mL, 15-mL, and 20-mL sizes. Berlex believes that prefilled syringes will save time and reduce the potential for contamination and needle stick incidents that might occur when Magnevist syringes are filled manually.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
